Welcome to the board. Definitely exciting times for CYDY and investors.

Not sure if your question is genuine, but yes biotech’s have many failed drugs (R&D) due to multiple reasons ranging from safety, efficacy, better drugs beat them to market, etc. As far as CytoDyn and leronlimab, it met its primary endpoint in a pivotal phase 3 trial and is pending BLA submission for approval for combo HIV. It has many additional indications for the same drug (leronlimab) that already has an outstanding safety record (zero drug related SAEs in over 850 patients, negligible toxicity and no documented resistance). It has shown promising results in other indications for mono HIV, HIV PrEP, cancer (potentially all metastatic cancers), NASH, GvHD, MS and likely more to follow when funding allows.

There is a plethora of information available here or the CytoDyn website. I recommend starting with the stickies at the top of this message board (from computer and not mobile version or app).